Ioannis Mantzaris

Ioannis Mantzaris

Oncology
111 East 210th Street
Bronx, NY 10461

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 75 publications

Graft-versus-host disease prophylaxis with abatacept plus intermediate dose cyclophosphamide for GVHD prophylaxis after peripheral blood stem transplantation: a single institution study.

Graft-versus-host disease prophylaxis with abatacept plus intermediate dose cyclophosphamide for GVHD prophylaxis after peripheral blood stem transplantation: a single institution study.

Journal: Bone marrow transplantation
Published: May 21, 2026

Pseudo-autologous Stem Cell Transplant for the Treatment of Secondary Central Nervous System Lymphoma.

Pseudo-autologous Stem Cell Transplant for the Treatment of Secondary Central Nervous System Lymphoma.

Journal: Cureus
Published: April 10, 2026

Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.

Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.

Journal: Haematologica
Published: January 13, 2026

A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemia.

A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemia.

Journal: Cancer immunology, immunotherapy : CII
Published: August 22, 2025

A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.

A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.

Journal: Leukemia
Published: August 11, 2025

CNS Involvement by North American-Adult T-cell Leukemia/Lymphoma Is Associated With Discrete Dissemination Patterns and Molecular Profiles, Involving XPO1 E571 and KLF2/PI3KCD in Selected Cases.

CNS Involvement by North American-Adult T-cell Leukemia/Lymphoma Is Associated With Discrete Dissemination Patterns and Molecular Profiles, Involving XPO1 E571 and KLF2/PI3KCD in Selected Cases.

Journal: JCO precision oncology
Published: July 25, 2025

Adding the FcRn antagonist efgartigimod for the prevention of IgG-mediated complications in the peri-transplant period.

Adding the FcRn antagonist efgartigimod for the prevention of IgG-mediated complications in the peri-transplant period.

Journal: Transfusion
Published: July 17, 2025

Cigarette smoking is associated with worse prognosis in myelodysplastic syndromes and hematopoietic alterations in murine models.

Cigarette smoking is associated with worse prognosis in myelodysplastic syndromes and hematopoietic alterations in murine models.

Journal: Leukemia & lymphoma
Published: June 09, 2025

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.

Journal: Blood
Published: January 30, 2025

Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia.

Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia.

Journal: Haematologica
Published: December 23, 2024

Use of the IgG degrader imlifidase for a poorly desensitized patient undergoing haematopoietic stem cell transplantation with donor-specific antibodies.

Use of the IgG degrader imlifidase for a poorly desensitized patient undergoing haematopoietic stem cell transplantation with donor-specific antibodies.

Journal: British journal of haematology
Published: November 15, 2024

Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study.

Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study.

Journal: JMIR cancer
Published: October 28, 2024
Showing 1-12 of 75

Last Updated: 09/26/2026